OTCMKTS:PRVCF PreveCeutical Medical (PRVCF) Stock Price, News & Analysis $0.0091 0.00 (-17.27%) As of 06/9/2026 12:28 PM Eastern Add Compare Share Share Stock Analysis Stock AnalysisChartShort InterestBuy This Stock About PreveCeutical Medical Stock (OTCMKTS:PRVCF) View Price History Chart DataSkip Price History Chart 1 Day 5 Days 30 Days 90 Days 1 Year Advanced 1 Day 1 Day 5 Days 30 Days 90 Days 1 Year Advanced Show volume Show extended hours Get PreveCeutical Medical alerts:Sign Up Key Stats Today's Range$0.0091▼$0.009150-Day Range$0.0090▼$0.018552-Week Range$0.00▼$0.04Volume1,000 shsAverage VolumeN/AMarket Capitalization$5.44 millionP/E RatioN/ADividend YieldN/APrice TargetN/AConsensus RatingN/A Company Overview PreveCeutical Medical Inc. is a biotechnology company focused on developing non-opioid therapies that target the endocannabinoid system through advanced translational medicine. The company leverages proprietary research in prebiotic and synthetic bioactive compounds to create drug candidates and wellness formulations aimed at addressing metabolic, inflammatory and neurodegenerative disorders. PreveCeutical’s science-driven approach emphasizes collaboration with leading academic institutions to translate laboratory discoveries into therapeutic solutions. Central to PreveCeutical’s development pipeline is PREV-IX7, a prebiotic drug candidate designed to modulate the gut microbiome for treatment of metabolic syndrome and related endocrine imbalances. The company also holds intellectual property on a novel synthetic cannabinoid analog intended to alleviate symptoms of fibromyalgia and irritable bowel syndrome. In parallel, PreveCeutical has advanced full-spectrum CBGa hemp extract formulations for consumer health and wellness products, supported by preclinical studies to establish safety and efficacy profiles. Founded in 2016 and headquartered in Brisbane, Australia, PreveCeutical maintains an operational presence in North America to facilitate commercialization activities. Under the leadership of Founder and Chief Executive Officer Konstantin Dobrovolski, the company partners with organizations such as the University of Queensland to drive its research and development agenda. PreveCeutical continues to pursue regulatory milestones and strategic alliances aimed at bringing its innovative therapies and wellness products to market.AI Generated. May Contain Errors. Read More Receive PRVCF Stock News and Ratings via Email Sign-up to receive the latest news and ratings for PreveCeutical Medical and its competitors with MarketBeat's FREE daily newsletter. Submit View SMS TermsSMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy. PRVCF Stock News HeadlinesPreveCeutical Announces Grant of Patent for Innovative Pain Therapy TechnologyDecember 4, 2025 | finance.yahoo.comPreveCeutical Reschedules Meeting and Announces Private PlacementAugust 22, 2025 | theglobeandmail.comTrump’s New Dollar revealedThe last time something like this happened was 1974 - a secret deal that quietly determined the financial fate of an entire generation. According to Porter Stansberry, founder of one of the largest independent financial research firms in the world, it is happening again. Fortune calls it 'the biggest change to the world's relationship with the dollar' in a generation. Stansberry says Trump's money reset - enacted through executive orders and a treaty signed by 13 nations in December 2025 called Pax Silica - could determine whether you are enriched or quietly impoverished by the shift already underway.June 10 at 1:00 AM | Porter & Company (Ad)PRVCF PreveCeutical Medical Inc. - Seeking AlphaJuly 2, 2025 | seekingalpha.comPreveCeutical Appoints Dr. Francis Tavares as CTO to Enhance Drug Discovery EffortsJune 30, 2025 | tipranks.comPreveCeutical Appoints Dr. Deepak Sampath as Corporate AdvisorJune 2, 2025 | tipranks.comPreveCeutical Appoints Stephen Glover as Corporate Advisor to Boost Strategic GrowthMay 26, 2025 | tipranks.comPreveCeutical Completes Private Placement to Boost R&D EffortsMay 22, 2025 | tipranks.comSee More Headlines PRVCF Stock Analysis - Frequently Asked Questions How have PRVCF shares performed this year? PreveCeutical Medical's stock was trading at $0.0177 at the beginning of the year. Since then, PRVCF shares have decreased by 48.6% and is now trading at $0.0091. How do I buy shares of PreveCeutical Medical? Shares of PRVCF stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. Company Calendar Today6/10/2026Fiscal Year End12/31/2026Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeOTCMKTS SectorMedical Industry MED - DRUGS Sub-IndustryN/A Current SymbolOTCMKTS:PRVCF CIKN/A Webwww.preveceutical.com Phone(604) 416-7777Fax778-945-6290EmployeesN/AYear FoundedN/AProfitability EPS (Trailing Twelve Months)N/A Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income-$1.13 million Net MarginsN/A Pretax MarginN/A Return on EquityN/A Return on Assets-470.30% Debt Debt-to-Equity RatioN/A Current Ratio0.04 Quick Ratio0.04 Sales & Book Value Annual SalesN/A Price / SalesN/A Cash FlowN/A Price / Cash FlowN/A Book Value($0.01) per share Price / Book-0.91Miscellaneous Outstanding Shares598,190,000Free FloatN/AMarket Cap$5.44 million OptionableNot Optionable BetaN/A A Guide To High-Short-Interest StocksMarketBeat's analysts have just released their top five short plays for June 2026. Learn which stocks have the most short interest and how to trade them. Click the link to see which companies made the list.Get This Free Report This page (OTCMKTS:PRVCF) was last updated on 6/10/2026 by MarketBeat.com Staff. From Our PartnersHe Called NVIDIA at $1.10 – Now He Says, “SELL”The analyst who called NVIDIA at $1.10 now says sell. According to Alexander Green, Chief Investment Strategis...The Oxford Club | SponsoredThe REAL Reason Trump is Invading IranFor a moment… Forget about Trump’s ties to Israel. Forget about reports of Iran’s nuclear program. Be...Banyan Hill Publishing | SponsoredOne hidden supplier shipped 5 billion parts to SpaceXMost investors are focused on the historic $1.75 trillion SpaceX IPO expected around June 30. But there's a le...Weiss Ratings | SponsoredYour book attachedBill Poulos is giving away his 'Safe Trade Options Formula' book for free - but only for a limited time throug...Profits Run | SponsoredLouis Navellier: My #1 AI stock for 2026 (name & ticker inside)Louis Navellier's Stock Grader system helped him flag Nvidia before its 82,000% run and has identified the top...InvestorPlace | SponsoredThis IPO Could Make SpaceX Look Small (Read before June 16)A red-hot AI startup just filed to go public - already valued at nearly $1 trillion. Wall Street veteran Marc ...Chaikin Analytics | SponsoredThe part that convinced me Joel is legitMost trading gurus cite big win rates but won't let you verify them. Joel Peterson is different - his trade pl...Crypto Swap Profits | SponsoredHow to claim a stake in SpaceX before the June 12 IPOSpaceX is expected to go public on June 12 - and for the first time, everyday investors may have a way in befo...Brownstone Research | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding PreveCeutical Medical Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share PreveCeutical Medical With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In Email Me a Login Link or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Free PRVCF Stock Alerts